{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:43:58Z","timestamp":1706197438615},"reference-count":3,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ygyno.2010.11.049","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T16:43:21Z","timestamp":1297874601000},"page":"426","source":"Crossref","is-referenced-by-count":6,"title":["Unexpected gastrointestinal toxicity from Docetaxel\/Carboplatin\/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III\/IV ovarian cancer, primary peritoneal, or fallopian tube cancer"],"prefix":"10.1016","volume":"121","author":[{"given":"Leona A.","family":"Holmberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Veljovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2010.11.049_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00000421-200106000-00001","article-title":"Are DNA ploidy and epidermal growth factor prognostic factor for untreated ovarian cancer? A prospective study","volume":"24","author":"Nagai","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.11.049_bb0010","first-page":"247","article-title":"EGF\/ErbB receptor family in ovarian cancer","volume":"107","author":"Maihle","year":"2002","journal-title":"Cancer Treat Res"},{"issue":"2","key":"10.1016\/j.ygyno.2010.11.049_bb0015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1054\/bjoc.2000.1572","article-title":"On behalf of the Scottish Gynaecological Cancer Trials Group. Docetaxel\u2013carboplatin as first-line chemotherapy for epithelial ovarian cancer","volume":"84","author":"Vasey","year":"2001","journal-title":"Br J Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T20:26:32Z","timestamp":1543955192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":3,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0090825811000667"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.11.049","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}